| Literature DB >> 34941178 |
Zheng Zhou1, Miaofa Ying, Rui Zhao.
Abstract
BACKGROUND: The purpose of this study was to evaluate the efficacy and safety of sevoflurane-remifentanil (SR) vs propofol-remifentanil (PR) as inhalation anesthesia or total intravenous anesthesia in patients undergoing craniotomy, respectively.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34941178 PMCID: PMC8702137 DOI: 10.1097/MD.0000000000028400
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1Flow diagram of screening studies in this meta-analysis.
Characteristics of the included studies.
| Dosage of maintenance anesthesia | |||||||||
| Study | Study design | No of centres | Sample size SR/PR | Mean age SR/PR | Specification of lesions | S+R | P+R | Outcomes | Jadad score |
| Sneyd et al, 2005 | RCTs | 1 | 26/24 | 58/56 | Not mentioned | 2%+ 0.5 μg/kg min | 2 μg/ml+0.5 μg/kg min | 1/2/3 | 5 |
| Citerio et al, 2012 | RCTs | 14 | 130/124 | – | Supratentorial neoplasm | (0.75–1.25)% + 0.25 μg/kg min | 6 mg/kg h+(0.05–0.1) μg/kg min | 2/7/8 | 4 |
| Lauta et al, 2010 | RCTs | 3 | 149/153 | 53.1/58.1 | Glioma meningioma | (0.7–2)% +(0.1– 0.25) μg/kg min | (6–10) mg/kg h+ (0.1–0.25) μg/kg min | 1/2/7/8 | 5 |
| Hernandez et al, 2006 | RCTs | 1 | 45/45 | – | Brain neoplasm | 0.4MAC + 0.25 μg/kg min | 2.5 μg/ml+0.25 μg/kg min | 1/2/8 | 3 |
| Pu et al, 2014 | RCTs | 1 | 30/30 | 44.5 | Tumor | (0.75–1.25)MAC+(2–4.5) ng/ml | 3 μg/ml+6ng/ml | 1 | 2 |
| Huang et al, 2018 | RCTs | 1 | 58/57 | 54.8/56.4 | Not mentioned | (0.75–1.25)MAC+(3–4)ng/ml | (3–4) μg/ml+(3–4)ng/ml | 1/2/4/5/6/8 | 4 |
| Wu et al, 2016 | RCTs | 1 | 43/43 | 45.2/46.3 | Craniocerebral trauma | 1.5%+3 μg/l | 2 mg/kg+3 μg/l | 1/2/3/9 | 3 |
| Wang et al, 2018 | RCTs | 1 | 30/30 | 52.22/52.39 | Not mentioned | (0.75–1.25)MAC +(3–5)ng/ml | (3–5) μg/ml+(3–5)ng/ml | 1/2/8 | 2 |
| Lin et al, 2008 | RCTs | 1 | 20/20 | – | Tumor | 2%+(0.2–0.4) μg/kg min | 3 μg/ml+(0.2–0.4) μg/kg min | 2/4/5/6 | 2 |
| Meng et al, 2009 | RCTs | 1 | 41/40 | 52 | Tumor | MAC≤1 + 2.0 ng/ml | 2.5 mg/ml+2.0 ng/ml | 1/2/9 | 2 |
| Ouyang et al, 2010 | RCTs | 1 | 20/20 | – | Tumor | (0.5–1.5)%+ (0.06–0.15) μg/kg min | (2–4) mg/kg h+(0.06–0.15) μg/kg min | 6/8/9 | 3 |
| Lei et al, 2017 | RCTs | 1 | 45/49 | 38.06/37.64 | Craniocerebral trauma | 1.5%+(0.1–0.3) μg/kg min | (2–4)mg/kg h+(0.1–0.3) μg/kg min | 1/2/3/6/9 | 2 |
| Yang et al, 2019 | RCTs | 1 | 77/78 | 55.8/56.2 | Craniocerebral trauma | (0.75–1.25)MAC +(3–5) ng/ml | (3–5) μg/ml+(3–5)ng/ml | 1/2/4/5/6/8 | 3 |
| Ren et al, 2008 | RCTs | 1 | 25/25 | 52/54 | Tumor | 1%+0.25 μg/kg min | 3 μg/ml+μg/kg min | 1/2/7/8 | 2 |
| Han et al, 2015 | RCTs | 1 | 20/20 | – | Not mentioned | 2%+ 0.2 μg/kg min | (4–12) mg/kg h+ 0.2 μg/kg min | 1/2/4/5/6/8/9 | 3 |
| Jin et al, 2015 | RCTs | 1 | 49/49 | 48.2/48.6 | Tumor | MAC = 1+0.2 μg/kg min | (1.5–2)mg/kg+ 0.2 μg/kg min | 1/2/4/5/6/8 | 2 |
| Bai et al, 2015 | RCTs | 1 | 70/58 | – | Tumor | MAC = 1.1–2.5+(0.1–0.2) μg/kg min | (4–5)mg/kg h + (0.1–0.25) μg/kg | 1/2/3/8 | 2 |
Note: 1, wake-up time; 2, extubation time; 3, spontaneous respiration time; 4, SBP = systolic blood pressure; 5, DBP = diastolic blood pressure, 6, heart rate; 7, brain relaxation score; 8, side effects; 9, MAP= mean arterial hypertension. MAC= Maximum alveolar concentration, PR = propofol-remifentanil, SR = sevoflurane-remifentanil.
Figure 2Funnel plot for assessing the risk of bias. SMD = standardized mean difference, SE = standard error.
Figure 3The effect of sevoflurane-remifentanil vs propofol-remifentanil on wake-up time.
Figure 4Comparison of the effect of sevoflurane-remifentanil and propofol-remifentanil on extubation time and spontaneous respiration time. A, extubation time; B, spontaneous respiration time.
Figure 5The effect of sevoflurane-remifentanil vs propofol-remifentanil on hemodynamic parameters. A, MAP, SBP, and heart rate; B, DBP. DBP = diastolic blood pressure, MAP = mean arterial hypertension, SBP = systolic blood pressure.
Figure 6The incidence of adverse reactions in patients undergoing craniotomy when used sevoflurane-remifentanil and propofol-remifentanil for anesthesia maintenance.